RQM+™ Selects THREAD to Power New Medical Device Research Offering
25.7.2023 13:00:00 EEST | Business Wire | Press release
RQM+, the world’s leading MedTech service provider, and THREAD, a leading decentralized research and eCOA provider, today announced the launch of a strategic partnership designed to transform the landscape of MedTech research.
This partnership will engage THREAD’s technology across RQM+’s portfolio of medical devices, diagnostic products, and digital therapies to support manufacturers with accelerating research and bringing new products to market faster. RQM+ customers can access innovative tools focused on transparency, speed, and agility that enable patient-focused studies to be conducted in the clinic, home, or on-the-go.
“Our strategic partnership enables MedTech clinical research, manufacturers, sites, and patients to unlock the potential for personalized breakthroughs and a future of targeted therapies. THREAD’s all-in-one platform provides a tailored approach for both manufacturers and patients, because at RQM+, we believe that every person deserves a unique path to better health,” said RQM+ Chief Operating Officer of Trial Services David Novotny. “Our strategic partnership with THREAD, combined with our complete MedTech lifecycle solutions, can unlock the potential to revolutionize clinical trials, enabling efficiencies, accelerating research, and transforming healthcare outcomes and leading medical advancements.”
“We are excited to combine our expertise and technologies with RQM+ in a solution dedicated to raising the bar for MedTech organizations. Our combined offering will provide RQM+ customers with a MedTech-focused research solution that supports everything from design to operations to regulatory submissions via a single customer experience,” said THREAD Co-Founder and CEO John Reites. “We are excited RQM+ selected THREAD as its partner to enable its new offering, which aligns with our mission to advance research for everyone, everywhere.”
Learn more about RQM+’s Patient First Medical Device Research Offering at https://www.rqmplus.com/services/clinical-trials.
About RQM+
RQM+ is the world's leading MedTech service provider offering consulting, clinical trial, lab, and reimbursement services, as well as technology solutions to support the entire product lifecycle. RQM+’s global team of clinical, technical, and top industry experts push the boundaries of excellence. With more former FDA, Medicines, and Healthcare Products Regulatory Agency (MHRA) and notified body regulators than any other firm, the RQM+ team has deep expertise in all clinical specialties. We reduce commercialization risk by offering a full complement of CRO services to progress medical devices, digital therapeutics and diagnostics onto the market and keep them there. In addition to early- and mid-stage MedTech companies, we currently work with 19 of the top 20 medical device manufacturers and seven of the top 10 IVD companies. For more information, visit RQMplus.com.
About THREAD
THREAD’s® purpose is to leverage its decentralized research platform to enable studies for everyone, everywhere. The company’s uniquely combined clinical research technology and consulting services help life science organizations to design, operate, and scale next-generation research studies and electronic clinical outcome assessments (eCOA) programs for participants, sites, and study teams. Through its comprehensive platform and scientific expertise, THREAD empowers studies to be accessible, efficient, and centered on the patient. Backed by health care investors Water Street Healthcare Partners and JLL Partners, THREAD is recognized as a leader by Everest Group’s Decentralized Clinical Trial Product PEAK Matrix® Assessment 2021/2022 and positioned in the Leader's Category of the 2022 IDC MarketScape for R&D Decentralized Clinical Trial Technology Solutions Vendor Assessment 2022. Visit Threadresearch.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230725695267/en/
Contact information
Rob Pepper
RQM+
RPepper@rqmplus.com
Les Yates
THREAD
Media@threadresearch.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom